**AI生物标志物分析公司Nucleai完成1400万美元B+轮融资，推动医疗预测技术革新**
以色列AI空间生物标志物分析初创公司Nucleai近日宣布，已成功获得1400万美元的B+轮融资，本轮融资由知名投资机构M Ventures领投。Nucleai的现有投资者，包括Section 32、Sanofi Ventures、Debiopharm、复星锐正资本、Vertex Ventures Israel和Grove Ventures等也积极参与了本轮投资。
Nucleai专注于利用人工智能和机器学习技术，对细胞和组织层面的病理图像及空间数据进行深度分析，以预测疾病的治疗效果。这一创新技术有望为医疗领域带来革命性的变革，提高临床决策的精准性和效率。
公司表示，新注入的资金将主要用于进一步研发其AI平台，提升在病理学和肿瘤学等领域的分析能力，同时加速产品商业化进程，以满足全球医疗市场对精准医疗解决方案日益增长的需求。
Nucleai的这一轮融资，不仅彰显了投资者对其技术潜力和市场前景的信心，也标志着AI在医疗生物标志物分析领域的应用正逐步走向成熟。通过将人工智能与生物医学研究相结合，Nucleai有望为患者提供更加个性化和高效的治疗方案，推动医疗科技的持续进步。
英语如下：
**AI Biomarker Analysis Firm Nucleai Secures $14M in B+ Round, Pioneering a New Era in Pathological Image Intelligence**
Keywords: AI bioanalysis, Nucleai funding,病理 image analysis
**Israeli AI Biomarker Company Nucleai Closes $14M B+ Funding Round, Advancing Medical Predictive Technology**
Nucleai, an Israeli startup specializing in AI-based spatial biomarker analysis, recently announced it has successfully raised $14 million in a B+ funding round led by prominent investor M Ventures. The round also saw participation from Nucleai’s existing investors, including Section 32, Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, and Grove Ventures.
Focusing on the deep analysis of病理 images and spatial data at the cellular and tissue level using artificial intelligence and machine learning, Nucleai aims to predict disease treatment outcomes. This innovative technology has the potential to revolutionize the medical field, enhancing the precision and efficiency of clinical decision-making.
The company plans to allocate the newly infused capital to further develop its AI platform, strengthening its analytical capabilities in pathology and oncology, while accelerating the commercialization of its products to cater to the growing global demand for precision medical solutions.
Nucleai’s funding round not only underscores investors’ confidence in its technological potential and market prospects but also signals the maturation of AI applications in medical biomarker analysis. By integrating AI with biomedical research, Nucleai is poised to offer more personalized and effective treatment options to patients, driving ongoing advancements in medical technology.
【来源】https://www.calcalistech.com/ctechnews/article/r11brac1a
Views: 1